{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:18:03Z","timestamp":1778631483796,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014189","name":"Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry","doi-asserted-by":"publisher","award":["322092-4"],"award-info":[{"award-number":["322092-4"]}],"id":[{"id":"10.13039\/501100014189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003624","name":"Ministry of Agriculture, Food and Rural Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003668","name":"Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002510","name":"Kongju National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002510","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Immunology and Immunopathology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.vetimm.2025.110923","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T02:05:52Z","timestamp":1743300352000},"page":"110923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Evaluation of clinical and immunological responses to recombinant canine interleukin-15 therapy in dogs with cancer: A pilot study"],"prefix":"10.1016","volume":"283","author":[{"given":"Y.J.","family":"Lim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.S.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.J.","family":"Baek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vetimm.2025.110923_bib1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vetimm.2025.110923_bib2","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1182\/blood-2008-12-189266","article-title":"Safety and immunologic effects of IL-15 administration in nonhuman primates","volume":"114","author":"Berger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2025.110923_bib3","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.cvsm.2014.05.003","article-title":"Metronomic chemotherapy in veterinary patients with cancer: rethinking the targets and strategies of chemotherapy","volume":"44","author":"Biller","year":"2014","journal-title":"Vet. Clin. North Am. Small Anim. Pr."},{"key":"10.1016\/j.vetimm.2025.110923_bib4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/j.1939-1676.2011.0753.x","article-title":"Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma","volume":"25","author":"Burton","year":"2011","journal-title":"J. Vet. Intern Med."},{"key":"10.1016\/j.vetimm.2025.110923_bib5","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.4049\/jimmunol.161.12.6977","article-title":"Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells","volume":"161","author":"Chapoval","year":"1998","journal-title":"J. Immunol."},{"key":"10.1016\/j.vetimm.2025.110923_bib6","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.canlet.2016.09.015","article-title":"Immunological, anti-angiogenic and clinical effects of intratumoral interleukin 12 electrogene therapy combined with metronomic cyclophosphamide in dogs with spontaneous cancer: a pilot study","volume":"400","author":"Cicchelero","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.vetimm.2025.110923_bib7","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1200\/JCO.2014.57.3329","article-title":"Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer","volume":"33","author":"Conlon","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vetimm.2025.110923_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1089\/jir.2018.0019","article-title":"Cytokines in the treatment of cancer","volume":"39","author":"Conlon","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.vetimm.2025.110923_bib9","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/vco.12203","article-title":"Immunological and angiogenic markers during metronomic temozolomide and cyclophosphamide in canine cancer patients","volume":"15","author":"Denies","year":"2017","journal-title":"Vet. Comp. Oncol."},{"key":"10.1016\/j.vetimm.2025.110923_bib10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1939-1676.2008.0179.x","article-title":"Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas","volume":"22","author":"Elmslie","year":"2008","journal-title":"J. Vet. Intern Med."},{"key":"10.1016\/j.vetimm.2025.110923_bib11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2025.110923_bib12","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","article-title":"Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy","volume":"13","author":"Fyfe","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.vetimm.2025.110923_bib13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.vetimm.2025.110923_bib14","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1189\/jlb.0408255","article-title":"CD5-low expression lymphocytes in canine peripheral blood show characteristics of natural killer cells","volume":"84","author":"Huang","year":"2008","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.vetimm.2025.110923_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001355","article-title":"Analysis of tumor-infiltrating NK and T cells highlights IL-15 stimulation and TIGIT blockade as a combination immunotherapy strategy for soft tissue sarcomas","volume":"8","author":"Judge","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.vetimm.2025.110923_bib16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/14789450.2020.1845654","article-title":"Multiomic analysis of cytokines in immuno-oncology","volume":"17","author":"Jurisic","year":"2020","journal-title":"Expert Rev. Proteom."},{"key":"10.1016\/j.vetimm.2025.110923_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M","article-title":"Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer","volume":"83","author":"Kammula","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.vetimm.2025.110923_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2021.155599","article-title":"Safety and immunological effects of recombinant canine IL-15 in dogs","volume":"148","author":"Lee","year":"2021","journal-title":"Cytokine"},{"key":"10.1016\/j.vetimm.2025.110923_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetimm.2015.04.002","article-title":"Generation of recombinant canine interleukin-15 and evaluation of its effects on the proliferation and function of canine NK cells","volume":"165","author":"Lee","year":"2015","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2025.110923_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3389\/fimmu.2018.00841","article-title":"Comparison of phenotypic and functional characteristics between canine non-B, non-T natural killer lymphocytes and CD3(+)CD5(dim)CD21(-) cytotoxic large granular lymphocytes","volume":"9","author":"Lee","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.vetimm.2025.110923_bib21","doi-asserted-by":"crossref","first-page":"5552","DOI":"10.1158\/1078-0432.CCR-18-0945","article-title":"Phase I trial of ALT-803, A novel recombinant IL15 complex, in patients with advanced solid tumors","volume":"24","author":"Margolin","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.vetimm.2025.110923_bib22","doi-asserted-by":"crossref","first-page":"11445","DOI":"10.1073\/pnas.200363097","article-title":"IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice","volume":"97","author":"Marks-Konczalik","year":"2000","journal-title":"Proc. Natl. Acad. Sci. Usa."},{"key":"10.1016\/j.vetimm.2025.110923_bib23","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.bbmt.2014.05.004","article-title":"Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: Implications for clinical therapy","volume":"20","author":"Miller","year":"2014","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.vetimm.2025.110923_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/cimm.1995.1216","article-title":"Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: Comparison with interleukin-2","volume":"165","author":"Munger","year":"1995","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.vetimm.2025.110923_bib25","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1002\/ijc.27801","article-title":"Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy","volume":"132","author":"Nars","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.vetimm.2025.110923_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.critrevonc.2011.04.009","article-title":"Cyclophosphamide-based metronomic chemotherapy: After 10 years of experience, where do we stand and where are we going? Crit","volume":"82","author":"Penel","year":"2012","journal-title":"Rev. Oncol. Hematol."},{"key":"10.1016\/j.vetimm.2025.110923_bib27","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/JLB.5MR0422-506R","article-title":"2022 update on the scientific premise and clinical trials for IL-15 agonists as cancer immunotherapy","volume":"112","author":"Peng","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.vetimm.2025.110923_bib28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004493","article-title":"Inhaled recombinant human IL-15 in dogs with naturally occurring pulmonary metastases from osteosarcoma or melanoma: a phase 1 study of clinical activity and correlates of response","volume":"10","author":"Rebhun","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.vetimm.2025.110923_bib29","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood-2017-12-823757","article-title":"First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation","volume":"131","author":"Romee","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2025.110923_bib30","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.vetimm.2013.03.006","article-title":"Ex vivo expansion of canine cytotoxic large granular lymphocytes exhibiting characteristics of natural killer cells","volume":"153","author":"Shin","year":"2013","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.vetimm.2025.110923_bib31","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1182\/blood-2011-09-377804","article-title":"IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+\u2009T effector memory population in peripheral blood","volume":"118","author":"Sneller","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.vetimm.2025.110923_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cytogfr.2014.09.001","article-title":"Interleukin-15: new kid on the block for antitumor combination therapy","volume":"26","author":"Van den Bergh","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.vetimm.2025.110923_bib33","first-page":"105","article-title":"Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy","volume":"14","author":"Waldmann","year":"2001","journal-title":"Immunity"}],"container-title":["Veterinary Immunology and Immunopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725000431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165242725000431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:39:42Z","timestamp":1778629182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165242725000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":33,"alternative-id":["S0165242725000431"],"URL":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.110923","relation":{},"ISSN":["0165-2427"],"issn-type":[{"value":"0165-2427","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of clinical and immunological responses to recombinant canine interleukin-15 therapy in dogs with cancer: A pilot study","name":"articletitle","label":"Article Title"},{"value":"Veterinary Immunology and Immunopathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vetimm.2025.110923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110923"}}